INNOVOTEX

Innovative new therapeutics based on

macrocycle mediated targeted drug delivery.

Pioneering macrocycle drug conjugates

INNOVOTEX is developing its proprietary platform of macrocycle drug conjugates (MDCs) as a new class
of antigen independent, tumor-targeting therapies to facilitate enhanced intracellular uptake.

SCIENCE

transforming the treatment paradigm

Clinical Validation

Increased Versatility

Platform leverages a clinically validated macrocycle used in >1000 patients.

Increased Versatility

Tumor localizing macrocycle core capable of carrying multi-modal payloads.

Market Expansion

Increased Versatility

Market Expansion

Optionality across multiple market indications resulting in new IP.

latest news

INNOVOTEX to present Breakthrough Data at the American Association of Cancer Research Annual Meeting!

NEWS

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept